Stephan Beck

Stephan Beck

Auto-generated profile, based on publicly available information

Stephan Beck

Medical Genomics, UCL Cancer Institute, University College London, London, UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2011 in Nature Reviews Genetics
Verified
Journal Article
Closed access
PDF file
VRVardhman K. Rakyan
Vardhman K. Rakyan
TDThomas A. Down
Thomas A. Down
DBDavid Balding
David Balding
SBStephan Beck
Stephan Beck

14 August 2017 in Bioinformatics
Verified
Journal Article
Open access
PDF file
YTYuan Tian
Yuan Tian
TMTiffany J Morris
Tiffany J Morris
AWAmy P Webster
Amy P Webster
ZYZhen Yang
Zhen Yang
SBStephan Beck
Stephan Beck
Andrew E. TeschendorffAndrew E. Teschendorff
Andrew E. Teschendorff
The Illumina Infinium HumanMethylationEPIC BeadChip is the new platform for high-throughput DNA methylation analysis, effectively doubling the coverage compared to the older 450 K array. Here we present a significantly updated and improved version of the Bioconductor package ChAMP, which can be used to analyze EPIC and 450k data. Many enhanced functionalities have been added, including correction for cell-type heterogeneity, network analysis and a series of interactive graphical user interfaces. ChAMP is a BioC package available from https://bioconductor.org/packages/release/bioc/html/ChAMP.html. Supplementary data are available at Bioinformatics online.

25 November 2019 in Genome Biology
Verified
Journal Article
Open access
PDF file
CBChristopher Bell
Christopher Bell
RLRobert Lowe
Robert Lowe
PAPeter D. Adams
Peter D. Adams
ABAndrea Baccarelli
Andrea Baccarelli
SBStephan Beck
Stephan Beck
VRVardhman K. Rakyan
Vardhman K. Rakyan
Epigenetic clocks comprise a set of CpG sites whose DNA methylation levels measure subject age. These clocks are acknowledged as a highly accurate molecular correlate of chronological age in humans and other vertebrates. Also, extensive research is aimed at their potential to quantify biological aging rates and test longevity or rejuvenating interventions. Here, we discuss key challenges to understand clock mechanisms and biomarker utility. This requires dissecting the drivers and regulators of age-related changes in single-cell, tissue- and disease-specific models, as well as exploring other epigenomic marks, longitudinal and diverse population studies, and non-human models. We also highlight important ethical issues in forensic age determination and predicting the trajectory of biological aging in an individual.

8 July 2008 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
TDThomas A Down
Thomas A Down
VRVardhman K Rakyan
Vardhman K Rakyan
DTDaniel J Turner
Daniel J Turner
PFPaul Flicek
Paul Flicek
HLHeng Li
Heng Li
SBStephan Beck
Stephan Beck

13 February 2017 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
Andrew E. TeschendorffAndrew E. Teschendorff
Andrew E. Teschendorff
CBCharles E. Breeze
Charles E. Breeze
SZShijie C. Zheng
Shijie C. Zheng
SBStephan Beck
Stephan Beck
Intra-sample cellular heterogeneity presents numerous challenges to the identification of biomarkers in large Epigenome-Wide Association Studies (EWAS). While a number of reference-based deconvolution algorithms have emerged, their potential remains underexplored and a comparative evaluation of these algorithms beyond tissues such as blood is still lacking. Here we present a novel framework for reference-based inference, which leverages cell-type specific DNAse Hypersensitive Site (DHS) information from the NIH Epigenomics Roadmap to construct an improved reference DNA methylation database. We show that this leads to a marginal but statistically significant improvement of cell-count estimates in whole blood as well as in mixtures involving epithelial cell-types. Using this framework we compare a widely used state-of-the-art reference-based algorithm (called constrained projection) to two non-constrained approaches including CIBERSORT and a method based on robust partial correlations. We conclude that the widely-used constrained projection technique may not always be optimal. Instead, we find that the method based on robust partial correlations is generally more robust across a range of different tissue types and for realistic noise levels. We call the combined algorithm which uses DHS data and robust partial correlations for inference, EpiDISH (Epigenetic Dissection of Intra-Sample Heterogeneity). Finally, we demonstrate the added value of EpiDISH in an EWAS of smoking. Estimating cell-type fractions and subsequent inference in EWAS may benefit from the use of non-constrained reference-based cell-type deconvolution methods.

1 April 2021 in Cell
Verified
Journal Article
Open access
EGEster Gangoso
Ester Gangoso
BSBenjamin Southgate
Benjamin Southgate
LBLeanne Bradley
Leanne Bradley
SRStefanie Rus
Stefanie Rus
FGFelipe Galvez-Cancino
Felipe Galvez-Cancino
SPSteven M. Pollard
Steven M. Pollard
Glioblastoma multiforme (GBM) is an aggressive brain tumor for which current immunotherapy approaches have been unsuccessful. Here, we explore the mechanisms underlying immune evasion in GBM. By serially transplanting GBM stem cells (GSCs) into immunocompetent hosts, we uncover an acquired capability of GSCs to escape immune clearance by establishing an enhanced immunosuppressive tumor microenvironment. Mechanistically, this is not elicited via genetic selection of tumor subclones, but through an epigenetic immunoediting process wherein stable transcriptional and epigenetic changes in GSCs are enforced following immune attack. These changes launch a myeloid-affiliated transcriptional program, which leads to increased recruitment of tumor-associated macrophages. Furthermore, we identify similar epigenetic and transcriptional signatures in human mesenchymal subtype GSCs. We conclude that epigenetic immunoediting may drive an acquired immune evasion program in the most aggressive mesenchymal GBM subtype by reshaping the tumor immune microenvironment.